Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
08 avr. 2024 16h30 HE
|
Cellectis Inc.
Cellectis announces that preliminary data exploring novel TALEN® editing process in HSPCs will be presented at ASGCT 2024
Monthly information on share capital and company voting rights
04 avr. 2024 16h30 HE
|
Cellectis Inc.
PARIS, April 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Monthly information on share capital and company voting rights
04 mars 2024 16h30 HE
|
Cellectis Inc.
PARIS, March 04, 2024 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
Monthly information on share capital and company voting rights
02 févr. 2024 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
29 janv. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
16 janv. 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
08 janv. 2024 16h30 HE
|
Cellectis Inc.
PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
22 déc. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
11 déc. 2023 07h00 HE
|
Marker Therapeutics
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis
06 déc. 2023 08h19 HE
|
Gallant Therapeutics
Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis